Gal3 also popped up as a target of the immune response when Kouo and colleagues interrogated sera from PDA patients enrolled in a phase II study before and after receiving GM-CSF vaccines and compared responders to non-responders [38] (Table 1). This evidence concerns the gene CSF2 and Patent ductus arteriosus.